OncoSec Medical Inc (OncoSec), a subsidiary of Grand Pharmaceutical Group Ltd, is a biotechnology company that focusses on designing and developing gene therapies, therapeutics and medical approaches. It offers services to stimulate body’s immune system and attack cancer. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. The company also identifies and develops novel immune-targeting agents for use with the immunogenicity platform. It conducts pre-clinical and clinical studies targeting various cancers in collaboration with various academic medical centers and companies. OncoSec is headquartered in San Diego, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company OncoSec Medical Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
OncoSec Medical Inc Company Overview
OncoSec Medical Inc Company Snapshot
OncoSec Medical Inc Pipeline Products and Ongoing Clinical Trials Overview
OncoSec Medical Inc – Pipeline Analysis Overview
OncoSec Medical Inc - Key Facts
OncoSec Medical Inc - Major Products and Services
OncoSec Medical Inc Pipeline Products by Development Stage
OncoSec Medical Inc Ongoing Clinical Trials by Trial Status
OncoSec Medical Inc Pipeline Products Overview
Diagnostic Tool - Melanoma
Diagnostic Tool - Melanoma Product Overview
GenPulse Device
GenPulse Device Product Overview
ImmunoPulse
ImmunoPulse Product Overview
ImmunoPulse Clinical Trial
NeoPulse - Head And Neck Cancer
NeoPulse - Head And Neck Cancer Product Overview
NeoPulse - Skin Cancer
NeoPulse - Skin Cancer Product Overview
Next Generation Electroporation Device
Next Generation Electroporation Device Product Overview
Jul 26, 2021: OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
Jun 24, 2021: OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer
Jun 14, 2021: OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering
May 27, 2021: OncoSec to Present at the Raymond James Human Health Innovation Conference
May 17, 2021: OncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance Management
Jun 22, 2020: OncoSec presents two late-breaking abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 27, 2020: OncoSec strengthens IP portfolio with three new patents covering TAVO and its electroporation gene delivery system
Mar 09, 2020: OncoSec announces that the class action and related litigation brought by by Alpha Holdings have been dismissed by Nevada State Court with Prejudice
Feb 11, 2020: OncoSec strengthens its Board of Directors with three new appointments
Feb 03, 2020: OncoSec's visceral lesion applicator (VLA) electroporation device demonstrates targeted entry and deployment in both lung and liver in data presented at the Society of Interventional Oncology Annual Meeting
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
OncoSec Medical Inc Pipeline Products and Ongoing Clinical Trials Overview
OncoSec Medical Inc Pipeline Products by Equipment Type
OncoSec Medical Inc Pipeline Products by Indication
OncoSec Medical Inc Ongoing Clinical Trials by Trial Status
OncoSec Medical Inc, Key Facts
OncoSec Medical Inc, Major Products and Services
OncoSec Medical Inc Number of Pipeline Products by Development Stage
OncoSec Medical Inc Pipeline Products Summary by Development Stage
OncoSec Medical Inc Ongoing Clinical Trials by Trial Status
OncoSec Medical Inc Ongoing Clinical Trials Summary
Diagnostic Tool - Melanoma - Product Status
Diagnostic Tool - Melanoma - Product Description
GenPulse Device - Product Status
GenPulse Device - Product Description
ImmunoPulse - Product Status
ImmunoPulse - Product Description
ImmunoPulse - A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer
NeoPulse - Head And Neck Cancer - Product Status
NeoPulse - Head And Neck Cancer - Product Description
NeoPulse - Skin Cancer - Product Status
NeoPulse - Skin Cancer - Product Description
Next Generation Electroporation Device - Product Status
Next Generation Electroporation Device - Product Description